ABPI response: UK joins Horizon Europe

Following the news that the UK is to join Horizon Europe, Janet Valentine, ABPI Executive Director, Innovation and Research Policy said: “Joining the Horizon Europe programme is a huge win for the scientific research community, who have been pushing for resolution over the past few years. UK innovation and research depends on international collaborations which are crucial for driving advancements in all areas of science, including the discovery and early development of new medicines and vaccines.

“The UK accession to Horizon enables the two sides to reinvigorate their longstanding partnership in R&D, and directly contributes to UK growth and competitiveness in the life sciences sector by making the UK an attractive destination for talented researchers.”

Last modified: 20 September 2023

Last reviewed: 20 September 2023

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.